GeoVax Labs Inc. (NASDAQ:GOVX) Sees Large Increase in Short Interest

GeoVax Labs Inc. (NASDAQ:GOVX) was the target of a significant increase in short interest in the month of August. As of August 31st, there was short interest totaling 367,575 shares, an increase of 101.6% from the August 15th total of 182,364 shares. Approximately 5.0% of the shares of the company are short sold. Based on an average daily volume of 2,024,690 shares, the short-interest ratio is currently 0.2 days.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on GOVX shares. Wall Street Zen upgraded GeoVax Labs from a “sell” rating to a “hold” rating in a research note on Sunday, June 21st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GeoVax Labs in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus price target of $150.00.

GeoVax Labs Stock Down 7.1%

Shares of GOVX stock traded down $0.03 during trading on Monday, reaching $0.43. 237,519 shares of the company’s stock were exchanged, compared to its average volume of 2,052,749. The firm’s fifty day moving average price is $0.76 and its 200-day moving average price is $1.28. The stock has a market capitalization of $3.17 million, a PE ratio of -0.04 and a beta of 3.66. GeoVax Labs has a twelve month low of $0.43 and a twelve month high of $17.78.

GeoVax Labs (NASDAQ:GOVX) last announced its quarterly earnings results on Monday, July 27th. The company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($2.16) by $1.19. As a group, analysts anticipate that GeoVax Labs will post -4.94 EPS for the current fiscal year.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.